Aldeyra Therapeutics Presents Noninfectious Anterior Uveitis Phase 2 Clinical Trial Data at the Association for Research in Vision and Ophthalmology 2017 Annual Meeting

Data Demonstrate ADX-102 Activity Comparable to Topical Ocular Corticosteroids But Without Known Corticosteroid Side Effects

LEXINGTON, MA--(Marketwired - May 17, 2017) - Aldeyra Therapeutics, Inc. ( NASDAQ : ALDX ) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to aldehydes, presented the results of a randomized, multi-center, investigator-masked, comparator-controlled, parallel-group Phase 2 clinical trial of topical ocular ADX-102, a first-in-class aldehyde trap, as an Emerging Treatments paper at the Association for Research in Vision and Ophthalmology (ARVO) 2017 Annual Meeting. Data from the trial demonstrated ADX-102 activity comparable to standard-of-care topical ocular corticosteroids in reducing anterior chamber cell count in patients with active noninfectious anterior uveitis (NAU). Unlike corticosteroid therapy, ADX-102 did not increase intraocular pressure, a major corticosteroid side effect that can lead to glaucoma, a potentially blinding chronic condition. Dr. John Sheppard, an internationally recognized expert in ocular inflammation, gave the presentation which is available on the investor relations page of the Aldeyra Therapeutics corporate website at ir.aldeyra.com .